Kidney Week

Abstract: SA-PO0866

Clinical Features, Histopathology, and Outcomes of Fibrillary Glomerulonephritis: A Spanish Multicenter Cohort

Session Information

• Glomerular Diseases: Management, Evolving Strategies, and Practice-Changing Advances
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Tatis, Efrain, Hospital Universitari Vall d'Hebron, Barcelona, CT, Spain

Efrain Tatis, MD

• Maskani, Ines, Fundacio Puigvert, Barcelona, CT, Spain

Ines Maskani

• Domínguez Guasch, Anna, Fundacio Puigvert, Barcelona, CT, Spain

Anna Domínguez Guasch, MD

• Moliz, Candela, Hospital Regional Universitario de Malaga, Málaga, AL, Spain

Candela Moliz

• González Cabrera, Fayna, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, CN, Spain

Fayna González Cabrera

• Cases Corona, Clara Maria, Hospital Universitario Fundacion Alcorcon, Alcorcón, Community of Madrid, Spain

Clara Maria Cases Corona, MD

• Ferri, Josefa Belen, Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Región de Murcia, Spain

Josefa Belen Ferri

• Cabello Pelegrin, Sheila, Hospital Universitari Son Espases, Palma, Mallorca, Spain

Sheila Cabello Pelegrin, MD

• Cannata-Ortiz, Pablo J., Hospital Universitario Fundacion Jimenez Diaz, Madrid, Community of Madrid, Spain

Pablo J. Cannata-Ortiz

• Osma, July Vanessa, Hospital Arnau de Vilanova, Valencia, Valencian Community, Spain

July Vanessa Osma

• Santos Collado, Natalia, Hospital Universitario Virgen del Rocio, Seville, AL, Spain

Natalia Santos Collado

• De La Flor, José C., Hospital Central de la Defensa Gomez Ulla, Madrid, Madrid, Spain

José C. De La Flor, APN

• Huerta, Ana, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, MD, Spain

Ana Huerta, MD

• Poma Saavedra, Fabrizzio, Hospital Comarcal de Vinaros, Vinaròs, Valencian Community, Spain

Fabrizzio Poma Saavedra

• Rodriguez Magariños, Catuxa, Complexo Hospitalario Universitario A Coruna Biblioteca, A Coruña, GA, Spain

Catuxa Rodriguez Magariños

• Carbayo, Javier, Hospital General Universitario Gregorio Maranon, Madrid, Community of Madrid, Spain

Javier Carbayo, MD, PhD

• Soler Romeo, Maria Jose, Hospital Universitari Vall d'Hebron, Barcelona, CT, Spain

Maria Jose Soler Romeo, MD, DrPH, MPH

Background

Fibrillary glomerulonephritis (FGN) is a rare glomerular disease with poor renal prognosis and limited therapeutic evidence. This study analyzed clinical and histopathological features, predictors of renal progression, and the impact of rituximab (RTX) in a Spanish multicenter cohort.

Methods

Retrospective multicenter study including 98 patients with biopsy-proven FGN from 15 Spanish hospitals. Outcomes were ESKD, mortality, and a composite of ESKD or ≥50% eGFR decline. Cox regression identified predictors of progression.

Results

Mean age was 60.3±10.9 years, median eGFR 40.5 mL/min/1.73 m2, and median proteinuria 3.25 g/day. During 32.2 months of follow-up, 36.7% progressed to ESKD and 15.3% died. RTX was associated with lower risk of ESKD (HR 0.36, 95% CI 0.16–0.80) and the composite renal outcome (HR 0.49, 95% CI 0.25–0.96), while higher creatinine, nephrotic-range proteinuria, and tubular atrophy predicted worse renal outcomes.

Conclusion

Baseline renal dysfunction, nephrotic-range proteinuria, and tubular atrophy were associated with poor prognosis in FGN. RTX therapy was associated with reduced renal progression, supporting its potential role in the management of this disease.

Baseline characteristics according to rituximab treatment

Abbreviations: SD = standard deviation; eGFR = estimated glomerular filtration rate; Continuous variables are presented as mean ± SD or median (P25–P75), as appropriate. Categorical variables are presented as n (%).